Evidence map›Paper›PMID 39537911›Full record

ArticleDrug delivery and translational research2025

Stable self-assembled oral metformin-bridged nanocochleates against hepatocellular carcinoma.

Mohamed G El-Melegy, Amal H El-Kamel, Radwa A Mehanna, Ahmed Gaballah, Hoda M Eltaher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamed G El-MelegyDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.ORCID 0000-0002-4569-0194
Amal H El-KamelDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.ORCID 0000-0001-8773-5365
Radwa A MehannaMedical Physiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID 0000-0001-9048-4464
Ahmed GaballahMicrobiology Department, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.ORCID 0000-0002-9038-6597
Hoda M EltaherDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. hoda.amin@alexpharmacy.edu.eg.ORCID 0000-0001-5602-2696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite its established anti-diabetic activity, Metformin hydrochloride (MET) has been repurposed for the management of hepatocellular carcinoma (HCC). Owing to MET high aqueous solubility and poor oral permeability, a novel nanoplatform is sought to overcome the current challenges of traditional formulations. In this study, we developed MET-bridged nanocochleates (MET-CO) using a direct bridging method followed by optimization and assessment using various in-vitro and in-vivo pharmacokinetic methods. The optimized nanocochleates MET-CO

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsMetforminNanoparticlesAdministration, OralAnimalsBiological AvailabilityCaco-2 CellsDrug LiberationHep G2 CellsHumansHypoglycemic AgentsMaleRatsRats, Sprague-DawleyAntineoplastic AgentsHypoglycemic AgentsMetforminCaco-2 transportEx-vivo permeationHepG2Metformin-bridged nanocochleatesOral bioavailabilityPharmacokinetics

Identifiers

PMID39537911
PMCPMC12037436

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.